Read the full article below. MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline 4 September, 2025 – Ghent, Belgium MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based...
The European Microbiome Innovation for Health (EMIH) highly welcomes the initiative of the European Commission to propose a European Biotech Act. This emerging sector needs a proper regulatory framework to ensure patients’ safety and timely access to innovative...
Paris, France, June 10, 2025 – On March 18, 2025, the Microbiome Times Forum, co-organized by the Microbiome Times together with EMIH (European Microbiome Innovation for Health) and MTIG (Microbiome Therapeutics Innovation Group), opened its doors to +500...
Paris, France, June 5, 2025 – The European Microbiome Innovation for Health (EMIH) announced a significant expansion, welcoming 13 new members, including private companies, public organizations, and a European patient advocacy group to its coalition....
MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg®. Xervyteg® has the potential if approved, to become the first microbiota...
Read the full article below. Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal...
